KCM
MLTX icon

Kennedy Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Kennedy Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,713
Closed -$1.34M – 730
2024
Q1 		$1.34M Sell
26,713
-8,622
-24% -$468K 0.03% 589
2023
Q4 		$2.13M Buy
+35,335
New +$1.82M 0.05% 479

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Kennedy Capital Management's MLTX Position: Q2 2024 in Review

Kennedy Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2024, closing a stake of 26,713 shares — an estimated $1.34M sold.

Kennedy Capital Management first reported a position in MLTX in Q4 2023 and held it in 2 quarters. The position peaked at $2.13M in Q4 2023. 111 funds tracked by Wall St. Rank hold MLTX as of Q2 2024.

  • Kennedy Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 26,713 MoonLake Immunotherapeutics shares in Q2 2024, an estimated $1.34M.
  • Kennedy Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2023 and held it in 2 quarters.
  • Kennedy Capital Management's MoonLake Immunotherapeutics position peaked at $2.13M in Q4 2023.
  • 111 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2024.

Based on Kennedy Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.